ImmunoGen

Home » ImmunoGen

Secondary

ImmunoGen

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.

Symbol

IMGN

Last Closing Price
$7.03

Shares
13,000,000

Anticipated Date
TBD

Underwriters
Jefferies, Leerink Partners, RBC Capital Markets

To view the prospectus for ImmunoGen, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253